Elderly Japanese patients with a high geriatric nutritional risk index (GNRI) were associated with significantly better Clostridioides difficile infection (CDI) relapse-free survival compared with ...

Please provide your email address to receive an email when new articles are posted on . Vowst, an oral fecal microbiota product, was approved by the FDA in April. Patients treated with the therapeutic ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Fecal microbiota ...

Randomized controlled trials had lower rates of success, but microbiota restoration still out-performed antibiotics. A new meta-analysis of studies examining the use of microbiota restoration to treat ...

Please provide your email address to receive an email when new articles are posted on . High-dose VE303 prevented more cases of recurrent C. difficile infection compared with a lower dose medication ...

“Since being founded by Flagship Pioneering over a decade ago, Seres has led the development of microbiome therapeutics, and today’s FDA approval of VOWST as the first orally administered ...

The addition of bezlotoxumab to fecal microbiota transplantation (FMT) does not provide any clear added benefit in patients with inflammatory bowel disease (IBD) and recurrent Clostridioides difficile ...

Three recent studies tackled strategies aimed at preventing recurrent Clostridium difficile infection (RCDI). Adding a single dose of bezlotoxumab—a monoclonal antibody that neutralized C difficile ...

Confirmatory results were announced from a phase 3 study investigating the oral microbiome therapeutic SER-109 for the treatment of recurrent Clostridioides difficile infection (CDI). SER-109 contains ...

Medical researchers have found that Fecal Microbiota Transplantation, or FMT, is an optimal cost-effective treatment for first recurrent Clostridioides difficile infection. Research recently published ...

The randomized, controlled, double-blind clinical trial included 46 patients who had three or more recurrences of CDI and had received a full course of vancomycin for their most recent acute episode.

Research recently published in Clinical Infectious Diseases from the University of Minnesota Medical School has found that Fecal Microbiota Transplantation, or FMT, is an optimal cost-effective ...